The genomic landscape of UC, including prevalent alterations in signaling pathways and driver genes, such as TP53, FGFR3, ERBB2, and PIK3CA, is closely associated with tumor development and aggressiveness, and affects treatment response (6). The gene discussed is TP53; the disease is neoplasm.